FDA committee backs Lilly's prasugrel

FDA staff say Eli Lilly's long-delayed blood thinner prasugrel has clear benefits compared with other anti-clotting meds on the market, but its use may need to be restricted to curb the potential of bleeding side effects; an advisory panel will review the potential new drug later this week. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.